drugset / Trial / NCT05658510
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
In this study, an investigational medication named BXCL501 is being tested for the treatment of episodes of agitation associated with bipolar I and bipolar II disorder, schizophrenia, schizoaffective and schizophreniform disorder. This study compares the study drug to a placebo.
Timeline
- Start
- 2022-11-21
- Primary completion
- 2025-08-15
- Completion
- 2025-08-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexmedetomidine | Other / unclassified | 60 ug | Other |
| Subject | Dexmedetomidine | Other / unclassified | 120 ug | Other |